Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | See Remarks | March 01, 2021 | March 03, 2021 |
| Keenova Therapeutics plcMNK · Entity 28960 | General Counsel | January 03, 2018 | January 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date March 01, 2021 · Filed March 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,588 |
Ending reported balance
After 2021-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-01 · Tax withholding · Disposed 799 · Balance 56,468 F1: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Row 2 · 2021-03-02 · Tax withholding · Disposed 880 · Balance 55,588 F1: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan.
Keenova Therapeutics plc
Report date January 03, 2018 · Filed January 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 16,342 |
Reported balance
After 2018-01-03 transaction · row 1
1 source rowRow 1 · 2018-01-03 · Tax withholding · Disposed 467 · Balance 16,342 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apria, Inc.
Report date March 29, 2022 · Filed March 29, 2022
Section 16 reporting ended · disclosed 2022-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-29 · Disposition to issuer · Disposed 10,370 · Balance 0 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4: Represents RSUs granted in 2021, which were originally scheduled to vest in three equal annual installments beginning on June 10, 2022. |
| LTIP UnitsSEC Table II · derivative / convertible security | Direct | 20,740 |
Reported balance
After 2022-03-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-29 · Grant · Acquired 20,740 · Balance 20,740 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F5: In connection with the Merger, certain long-term incentive plan units ("LTIP") were vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such LTIP immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F6: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period. |
| LTIP UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-29 · Disposition to issuer · Disposed 20,740 · Balance 0 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F5: In connection with the Merger, certain long-term incentive plan units ("LTIP") were vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such LTIP immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F6: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee.
F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.
F4: Represents RSUs granted in 2021, which were originally scheduled to vest in three equal annual installments beginning on June 10, 2022.
F5: In connection with the Merger, certain long-term incentive plan units ("LTIP") were vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such LTIP immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.
F6: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2022 Filed Mar 29, 2022 16:31 UTC | Apria, Inc. APR · Entity 15495 | Disposition to issuerLTIP Units · Derivative | 20,740 | $37.50 | $777,750.00 |
DisclosureSEC source: 0000899243-22-012664 · doc4.xml · derivative · entry 3 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,740 shares Expires not disclosed F2 · derivative.exercise_price: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1 · kind: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F5 · kind: In connection with the Merger, certain long-term incentive plan units ("LTIP") were vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such LTIP immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F5 · price: In connection with the Merger, certain long-term incentive plan units ("LTIP") were vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such LTIP immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F6 · derivative.exercise_date: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period. F6 · derivative.expiration_date: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period. Read SEC document |
| March 29, 2022 Filed Mar 29, 2022 16:31 UTC | Apria, Inc. APR · Entity 15495 | GrantLTIP Units · Derivative | 20,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012664 · doc4.xml · derivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,740 Underlying: Common Stock · 20,740 shares Expires not disclosed F2 · derivative.exercise_price: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F5 · kind: In connection with the Merger, certain long-term incentive plan units ("LTIP") were vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such LTIP immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F6 · derivative.exercise_date: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period. F6 · derivative.expiration_date: Represents LTIP awards granted in 2020 which were originally scheduled to vest in equal quarterly installments beginning on March 31, 2020, subject to the satisfaction of certain performance criteria as determined at the end of the three year performance period. Read SEC document |
| March 29, 2022 Filed Mar 29, 2022 16:31 UTC | Apria, Inc. APR · Entity 15495 | Disposition to issuerRestricted Stock Units · Derivative | 10,370 | $37.50 | $388,875.00 |
DisclosureSEC source: 0000899243-22-012664 · doc4.xml · derivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,370 shares Expires not disclosed F2 · derivative.exercise_price: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1 · kind: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4 · derivative.exercise_date: Represents RSUs granted in 2021, which were originally scheduled to vest in three equal annual installments beginning on June 10, 2022. F4 · derivative.expiration_date: Represents RSUs granted in 2021, which were originally scheduled to vest in three equal annual installments beginning on June 10, 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 19:38 UTC | Apria, Inc. APR · Entity 15495 | GrantRestricted Stock Units · Derivative | 10,370 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-023690 · doc4.xml · derivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,370 Underlying: Common Stock · 10,370 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer ("Common Stock"). The restricted stock units will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee. F2 · derivative.exercise_date: These restricted stock units vest in three equal annual installments beginning on June 10, 2022, subject to the Reporting Person's continued employment on the applicable vesting date. F2 · derivative.expiration_date: These restricted stock units vest in three equal annual installments beginning on June 10, 2022, subject to the Reporting Person's continued employment on the applicable vesting date. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 18:52 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 880 | $32.34 | $28,459.20 |
DisclosureSEC source: 0000950138-21-000178 · edgar.xml · nonDerivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,588 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:52 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 799 | $33.65 | $26,886.35 |
DisclosureSEC source: 0000950138-21-000178 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,468 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 17:17 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 6,533 | $30.58 | $199,779.14 |
DisclosureSEC source: 0000950138-21-000143 · edgar.xml · nonDerivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,267 F2 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of performance-based restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 17:17 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 21,663 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-21-000143 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,800 F1 · price: Vesting of performance-based restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 17:32 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-20-000120 · edgar.xml · nonDerivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,137 F2 · price: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 2, 2020, one-third vesting on March 2, 2021, one-third vesting on March 2, 2022, and the remaining vesting on March 2, 2023. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:32 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 799 | $27.40 | $21,892.60 |
DisclosureSEC source: 0000950138-20-000120 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,137 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 07:46 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 11,030 | $26.65 | $293,905.38 |
DisclosureSEC source: 0000950138-19-000470 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,936 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.65 to $26.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:42 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 8,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000110 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,906 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 18:11 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 29,383 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0000950138-18-000566 · edgar.xml · derivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,383 Underlying: Elanco Animal Health Inc. Common Stock · 29,383 shares Expires 2028-10-20 F2 · price: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. F2 · derivative.exercise_date: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 18:11 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 9,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000566 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,725 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 16:14 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 5,000 | $24.00 | $120,000.00 |
DisclosureSEC source: 0001140361-18-039142 · form4.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| January 03, 2018 Filed Jan 6, 2018 00:50 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 467 | $23.51 | $10,979.17 |
DisclosureSEC source: 0000950138-18-000059 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,342 Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:10 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 7,900 | $20.80 | $164,308.94 |
DisclosureSEC source: 0000950138-17-000748 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,809 F1 · balance_after: Includes 530 shares acquired between January 1, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 20:10 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 260 | $44.57 | $11,588.20 |
DisclosureSEC source: 0000950138-17-000355 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,379 Read SEC document |
| March 07, 2017 Filed Mar 8, 2017 13:46 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 290 | $50.35 | $14,601.50 |
DisclosureSEC source: 0000950138-17-000290 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,639 F1 · balance_after: Includes 406 shares acquired between April 6, 2016 and December 31, 2016 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:59 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 27,151 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000016 · edgar.xml · derivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,151 Underlying: Ordinary Shares · 27,151 shares Expires 2027-01-03 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:59 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 4,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000016 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,943 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.